Published in Aliment Pharmacol Ther on December 29, 2010
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J Clin Invest (2012) 2.62
Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology (2013) 2.03
Paediatric gastroenterology evaluation of overweight and obese children referred from primary care for suspected non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2013) 1.44
Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res (2011) 1.42
Nonalcoholic fatty liver disease (NAFLD) proven by transient elastography in patients with coronary heart disease. Wien Klin Wochenschr (2014) 1.37
Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease. PLoS One (2012) 1.28
Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol (2014) 1.25
Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev (2012) 1.05
Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol (2014) 1.05
Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. World J Hepatol (2015) 1.00
What is the role of adiponectin in obesity related non-alcoholic fatty liver disease? World J Gastroenterol (2013) 0.99
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Mayo Clin Proc (2015) 0.90
Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. PLoS One (2014) 0.88
Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link? Gastroenterol Res Pract (2014) 0.88
Association between platelet count as a noninvasive marker and ultrasonographic grading in patients with nonalcoholic Fatty liver disease. Hepat Mon (2015) 0.87
Usefulness of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging in assessment of non-alcoholic fatty liver disease. Eur Radiol (2014) 0.87
Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig (2013) 0.87
NIKEI: a new inexpensive and non-invasive scoring system to exclude advanced fibrosis in patients with NAFLD. PLoS One (2013) 0.86
An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD). Ther Adv Endocrinol Metab (2011) 0.86
Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep (2015) 0.84
The Global Nonalcoholic Fatty Liver Disease Epidemic: What a Radiologist Needs to Know. J Clin Imaging Sci (2015) 0.82
Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. Am J Gastroenterol (2015) 0.82
Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: a large-scale cross-sectional study in Japan. BMC Gastroenterol (2015) 0.82
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol (2015) 0.81
Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol (2015) 0.80
NAFLD and Chronic Kidney Disease. Int J Mol Sci (2016) 0.79
Nonalcoholic fatty liver disease (NAFLD) - a new factor that interplays between inflammation, malnutrition, and atherosclerosis in elderly hemodialysis patients. Clin Interv Aging (2014) 0.79
Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease. Wien Klin Wochenschr (2014) 0.79
Systematic analysis of the gene expression in the livers of nonalcoholic steatohepatitis: implications on potential biomarkers and molecular pathological mechanism. PLoS One (2012) 0.79
Ghrelin-ghrelin O-acyltransferase system in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol (2015) 0.79
Serum TGF-β, Serum MMP-1, and HOMA-IR as non-invasive predictors of fibrosis in Egyptian patients with NAFLD. Saudi J Gastroenterol (2012) 0.78
Association of Non-alcoholic Fatty Liver Disease with Metabolic Syndrome Independently of Central Obesity and Insulin Resistance. Sci Rep (2016) 0.78
Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease. Wien Klin Wochenschr (2015) 0.78
Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS One (2016) 0.78
Inhibition of apoptosis in the management of nonalcoholic fatty liver disease. World J Gastrointest Pharmacol Ther (2013) 0.78
Nonalcoholic Fatty liver disease and psoriasis: what a dermatologist needs to know. J Clin Aesthet Dermatol (2015) 0.78
Biochemical Evaluation of Patients of Alcoholic Liver Disease and Non-alcoholic Liver Disease. Indian J Clin Biochem (2013) 0.77
Relevance of low testosterone to non-alcoholic fatty liver disease. Cardiovasc Endocrinol (2015) 0.77
Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol (2015) 0.76
Glycosyltransferases and non-alcoholic fatty liver disease. World J Gastroenterol (2016) 0.76
Acute steatohepatitis, due to extreme metabolic dysregulation, as the first presentation of non-alcoholic fatty liver disease. Clin Pract (2013) 0.75
Evaluation of Basal Serum Adrenocorticotropic Hormone and Cortisol Levels and Their Relationship with Nonalcoholic Fatty Liver Disease in Male Patients with Idiopathic Hypogonadotropic Hypogonadism. Chin Med J (Engl) (2016) 0.75
Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography. PLoS One (2017) 0.75
Effects of cumin on nonalcoholic steatohepatitis: A double blind, randomised, controlled trial. Adv Biomed Res (2015) 0.75
Association between sonographic diagnosis of fatty liver with histopathologic abnormalities and liver biopsy findings in middle age patient with non-alcoholic fatty liver disease. Adv Biomed Res (2016) 0.75
The diagnosis of non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2012) 0.75
Multifeature analysis of an ultrasound quantitative diagnostic index for classifying nonalcoholic fatty liver disease. Sci Rep (2016) 0.75
Predicting Hepatic Steatosis in Living Liver Donors via Noninvasive Methods. Medicine (Baltimore) (2016) 0.75
The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. Am J Gastroenterol (2016) 0.75
Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol (2017) 0.75
The clinical significance of serum ferritin in pediatric non-alcoholic Fatty liver disease. Pediatr Gastroenterol Hepatol Nutr (2014) 0.75
Prediction and Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) and Identification of Its Associated Factors Using the Classification Tree Method. Iran Red Crescent Med J (2016) 0.75
AGTR1 rs3772622 gene polymorphism increase the risk of nonalcoholic fatty liver disease patients suffer coronary artery disease in Northern Chinese Han population. Lipids Health Dis (2016) 0.75
Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Caspian J Intern Med (2016) 0.75
Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran. Hepat Mon (2015) 0.75
Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis. Clin Mol Hepatol (2013) 0.75
Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol (2017) 0.75
Molecular MR Imaging of Myeloperoxidase Distinguishes Steatosis from Steatohepatitis in Nonalcoholic Fatty Liver Disease. Radiology (2017) 0.75
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (2004) 18.86
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology (1999) 11.76
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (2006) 10.05
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest (2005) 9.09
Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology (2003) 8.75
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology (2005) 7.03
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology (1990) 6.53
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77
Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology (1999) 5.75
The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology (2002) 5.70
Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR) Diabet Med (1999) 5.59
FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology (2007) 5.53
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (2005) 5.11
Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology (2003) 4.95
Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology (2007) 4.83
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology (2006) 4.60
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology (2010) 4.43
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care (2007) 4.42
Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev (2002) 4.41
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology (2008) 4.28
Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med (2010) 4.14
Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol (2008) 4.01
Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology (1999) 3.99
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut (2008) 3.88
Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology (2008) 3.67
The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol (2006) 3.62
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (2008) 3.60
Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology (2007) 3.58
Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut (2007) 3.58
Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology (2004) 3.23
Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol (2008) 3.16
Serum adipokine levels predictive of liver injury in non-alcoholic fatty liver disease. Liver Int (2009) 3.12
Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol (2008) 3.03
Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology (2006) 3.02
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology (2009) 2.92
Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol (2008) 2.87
Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology (2010) 2.86
Causes and metabolic consequences of Fatty liver. Endocr Rev (2008) 2.84
The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Dig Liver Dis (2006) 2.83
The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology (2010) 2.75
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut (2010) 2.66
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology (2010) 2.58
Pathogenesis of non-alcoholic fatty liver disease. QJM (2009) 2.50
Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol (2009) 2.43
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (2009) 2.42
Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology (2009) 2.39
A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology (2005) 2.38
From fat to inflammation. Gastroenterology (2006) 2.35
Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther (2007) 2.31
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol (2007) 2.29
Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology (2008) 2.23
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut (2010) 2.20
A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg (2008) 2.20
Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol (1998) 2.13
Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol (2004) 2.11
Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci (1995) 2.06
Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive. Semin Liver Dis (2008) 2.04
Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol (2003) 2.01
Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology (2009) 2.00
Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci (1997) 1.99
Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology (2009) 1.97
Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology (2000) 1.96
Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology (1988) 1.91
Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol (2006) 1.90
The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg (2004) 1.83
Histological assessment of non-alcoholic fatty liver disease. Histopathology (2006) 1.80
Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol (2007) 1.78
The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol (2009) 1.77
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol (2010) 1.70
Apoptosis in alcoholic and nonalcoholic steatohepatitis. Front Biosci (2005) 1.63
Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance? Hepatology (2010) 1.60
Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol (2010) 1.60
Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) (2008) 1.59
Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis (2009) 1.58
The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol (2005) 1.54
Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol (2007) 1.50
Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology (2005) 1.50
Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol (2009) 1.50
Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol (2007) 1.49
Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol (2007) 1.48
Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2006) 1.47
AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol (2008) 1.45
NASH: a mitochondrial disease. J Hepatol (2005) 1.45
Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg (2005) 1.42
Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int (2006) 1.40
Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol Hepatol (2008) 1.36
Nine-year incident diabetes is predicted by fatty liver indices: the French D.E.S.I.R. study. BMC Gastroenterol (2010) 1.34
Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction. Hepatology (2004) 1.33
Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. BMJ (2012) 5.28
Pathogenesis of non-alcoholic fatty liver disease. QJM (2009) 2.50
Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance? Clin Endocrinol (Oxf) (2008) 2.15
11beta-Hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia (2008) 1.07
A novel selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitor prevents human adipogenesis. J Endocrinol (2008) 1.06
11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab (2004) 1.05
Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): a prospective cohort study. Health Technol Assess (2013) 1.02
Expression profiling of 11beta-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes. J Mol Endocrinol (2006) 1.01
Which hepatocyte will it be? Hepatocyte choice for bioartificial liver support systems. Liver Transpl (2001) 1.01
Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab (2011) 1.00
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment Pharmacol Ther (2012) 0.98
Central hypoadrenalism. J Clin Endocrinol Metab (2014) 0.90
Referral patterns and social deprivation in paracetamol-induced liver injury in Scotland. Lancet (2001) 0.89
Prothrombin time to assess fulminant hepatic failure. Lancet (2002) 0.89
Adrenal suppression in bronchiectasis and the impact of inhaled corticosteroids. Eur Respir J (2008) 0.87
Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT). J Clin Endocrinol Metab (2015) 0.86
Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Horm Res (2001) 0.85
Effects of the 5-HT2C receptor agonist meta-chlorophenylpiperazine on appetite, food intake and emotional processing in healthy volunteers. Psychopharmacology (Berl) (2014) 0.84
Abdominal subcutaneous adipose tissue insulin resistance and lipolysis in patients with non-alcoholic steatohepatitis. Diabetes Obes Metab (2014) 0.84
Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut (2012) 0.82
An improved ex vivo method of primary porcine hepatocyte isolation for use in bioartificial liver systems. Eur J Gastroenterol Hepatol (2000) 0.80
Long-term impact of liver transplantation on respiratory function and nutritional status in children and adults with cystic fibrosis. Am J Transplant (2012) 0.78
Corticosteroids, 11beta-hydroxysteroid dehydrogenase isozymes and the rabbit choroid plexus. J Neuroendocrinol (2007) 0.77
Short- and long-term glucocorticoid treatment enhances insulin signalling in human subcutaneous adipose tissue. Nutr Diabetes (2011) 0.76
Editorial: Treatment for NASH - helping the liver or helping the heart? Aliment Pharmacol Ther (2015) 0.75
Platelet basal cytosolic calcium: the influence of plasma factors in cirrhosis. J Hepatol (1996) 0.75